ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
PHASE3
This study is designed to compare the safety and efficacy of ASKC202 combin...
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
PHASE2
This clinical trial aims to evaluate the efficacy and safety of neoadjuvant...
Status
Not Yet Recruiting
Location
Affiliated Cancer Hospital and Institute of Guangzhou Medical Univercity